BACKGROUND Postoperative nausea and vomiting is a distressing complication of surgery, and 5-HT3 receptor antagonists are often prescribed to prevent it. Ondansetron is the agent typically administered to prevent postoperative nausea and vomiting. Although ramosetron has a longer duration of action than ondansetron, it remains unclear whether ramosetron is the more effective medication. We perf...

IMPLICATIONS We present evidence-based guidelines developed by an international panel of experts for the management of postoperative nausea and vomiting.

Postoperative nausea and vomiting (PONV) are still common following surgery. This is not only distressing to the patient, but increases costs. The thorough understanding of the mechanism of nausea and vomiting and a careful assessment of risk factors provide a rationale for appropriate management of PONV. Strategy to reduce baseline risk and the adoption of a multimodal approach will most likel...

Previous randomized controlled trials have reported conflicting findings on the superiority of palonosetron over ramosetron for preventing postoperative nausea and vomiting (PONV). Therefore, the present systematic review was registered in PROSPERO (CRD42016038120) and performed to compare the efficacy of perioperative administration of palonosetron to that of ramosetron for preventing PONV. We...

Postoperative nausea and vomiting (PNV) in the ambulatory surgical unit is a continuing and vexing problem. Delayed discharges and patient discomfort have major impact in an outpatient setting. An understanding of the causes and aetiologies of PNV including anaesthetic, surgical and patient factors is critically important in the management of these patients. Therapy begins with a good history, ...